Marinaki S, Kolovou K, Sakellariou S, Boletis JN, Delladetsima IK. Hepatitis B in renal transplant patients. World J Hepatol 2017; 9(25): 1054-1063 [PMID: 28951777 DOI: 10.4254/wjh.v9.i25.1054]
Corresponding Author of This Article
Ioanna K Delladetsima, PhD, Professor, First Department of Pathology, Medical School, University of Athens, Mikras Asia 75, Goudi, 11527 Athens, Greece. idelladet@med.uoa.gr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Sep 8, 2017; 9(25): 1054-1063 Published online Sep 8, 2017. doi: 10.4254/wjh.v9.i25.1054
Hepatitis B in renal transplant patients
Smaragdi Marinaki, Kyriaki Kolovou, Stratigoula Sakellariou, John N Boletis, Ioanna K Delladetsima
Smaragdi Marinaki, Kyriaki Kolovou, John N Boletis, Department of Nephrology and Renal Transplantation Unit, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
Stratigoula Sakellariou, Ioanna K Delladetsima, First Department of Pathology, Medical School, University of Athens, 11527 Athens, Greece
Author contributions: Delladetsima IK and Boletis JN designed the review; Marinaki S drafted the paper; Kolovou K selected and categorized the literature; Sakellariou S wrote the histological part of the review and participated in the editing; Delladetsima IK revised the manuscript.
Conflict-of-interest statement: None declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ioanna K Delladetsima, PhD, Professor, First Department of Pathology, Medical School, University of Athens, Mikras Asia 75, Goudi, 11527 Athens, Greece. idelladet@med.uoa.gr
Telephone: +30-21-7462186 Fax: +30-21-7462157
Received: January 26, 2017 Peer-review started: February 8, 2017 First decision: June 12, 2017 Revised: August 6, 2017 Accepted: August 15, 2017 Article in press: August 16, 2017 Published online: September 8, 2017
Core Tip
Core tip: Though decreasing, hepatitis B still remains a considerable problem, especially in high-risk patient populations as kidney transplant recipients. The widespread use of new antivirals and the introduction of universal prophylaxis immediately after transplantation have changed the picture in hepatitis B virus (HBV) (+) transplantation. Long term survival rates of HBV(+) recipients are approaching those of HBV(-), altering HBV(+) kidney transplantation from a “high risk” procedure into routine practice. Furthermore, accumulating evidence confirms the safety of transplantation from HBsAg(+) donors into immunized recipients. All immunosuppressants can be used in HBV(+) transplantation and total immunosuppression must be kept at the lowest possible levels long term.
